Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Agios Pharmaceuticals (NASDAQ:AGIO), which has seen a strong 20% return year-to-date, reported that Chief Medical (TASE:BLWV) Officer Sarah Gheuens sold 11,914 shares of common stock on July 9, 2025, for a total of $452,601. According to InvestingPro analysis, the stock is currently trading below its Fair Value. The sales were executed at prices ranging from $37.93 to $38.76.
On the same day, Gheuens also exercised stock options to acquire 11,914 shares of Agios Pharmaceuticals common stock at a price of $25.01, for a total value of $297,969. Following these transactions, Gheuens directly owns 61,271 shares of Agios Pharmaceuticals.
The sale was effected pursuant to a Rule 10b5-1 trading plan. The company maintains a strong financial position with a current ratio of 18.5, indicating robust liquidity to meet short-term obligations.
In other recent news, Agios Pharmaceuticals has appointed Jay Backstrom, M.D., M.P.H., to its Board of Directors, a move that aligns with the company’s focus on advancing its pipeline of rare disease medicines. Dr. Backstrom brings extensive experience from his previous roles at Scholar Rock and Celgene Corporation (NASDAQ:CELG). In parallel developments, TD Cowen has reiterated its buy rating on Agios, expressing confidence in the company’s mitapivat drug ahead of key clinical trial results. The firm anticipates significant sales potential for mitapivat in sickle cell disease and thalassemia.
Additionally, H.C. Wainwright adjusted its price target for Agios to $56.00 from $61.00, while maintaining a buy rating. This adjustment follows a new commercial agreement with Avanzanite Bioscience for the distribution of PYRUKYND® in Europe, the UK, and Switzerland. This partnership aims to expand the availability of the drug for pyruvate kinase deficiency, a rare condition.
Agios Pharmaceuticals’ collaboration with Avanzanite is expected to enhance the company’s market presence in Europe. The recent developments, including the distribution agreement and analyst ratings, reflect the company’s ongoing efforts to maximize its commercial growth and innovation in the rare disease sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.